FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

(MedPage Today) -- The FDA approved capivasertib (Truqap) in combination with abiraterone (Zytiga) and prednisone for PTEN-deficient prostate cancer, the agency announced on Friday. Approval stipulates use in metastatic hormone-sensitive prostate...
Source
MedPage Today
Opens original article in a new tab



